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Abstract
 
Recent evidence suggests that in addition to their well known stimulatory properties, dendritic
cells (DCs) may play a major role in peripheral tolerance. It is still unclear whether a distinct
subtype or activation status of DC exists that promotes the differentiation of suppressor rather
than effector T cells from naive precursors. In this work, we tested whether the naturally oc-
curring CD4
 
  
 
CD25
 
  
 
regulatory T cells (Treg) may control immune responses induced by
DCs in vivo
 
.
 
 We characterized the immune response induced by adoptive transfer of antigen-
pulsed mature DCs into mice depleted or not of CD25
 
  
 
cells. We found that the development
of major histocompatibility complex class I and II–restricted interferon 
 
 
 
–producing cells was
consistently enhanced in the absence of Treg. By contrast, T helper cell (Th)2 priming was
down-regulated in the same conditions. This regulation was independent of interleukin 10
production by DCs. Of note, splenic DCs incubated in vitro with Toll-like receptor ligands
(lipopolysaccharide or CpG) activated immune responses that remained sensitive to Treg
function. Our data further show that mature DCs induced higher cytotoxic activity in CD25-
depleted recipients as compared with untreated hosts. We conclude that Treg naturally exert a
negative feedback mechanism on Th1-type responses induced by mature DCs in vivo
 
.
 
Key words: primary response • T helper cell type 1/type 2 balance • regulation • inﬂammation • 
Toll-like receptors
 
Introduction
 
Regulatory T cells (Treg)
 
* 
 
are diverse and include at least
three populations that differ by their phenotype, cytokine
secretion profile, and suppressive mechanism. Tr1 cells
have been shown to produce high levels of IL-10 and
TGF-
 
 
 
, and require IL-10 for their differentiation and
function. Th3 cells produce TGF-
 
 
 
, IL-10, and IL-4,
and suppress via a TGF-
 
 
 
–dependent mechanism. CD4
 
 
 
CD25
 
  
 
cells constitutively express the IL-2R
 
  
 
(CD25), in-
hibit IL-2 production, and promote cell cycle arrest in
CD4
 
  
 
and CD8
 
  
 
T cells by a mechanism that requires cell
to cell contact, is largely independent on IL-10, and par-
tially dependent on TGF-
 
 
 
. Once activated through their
T cell receptor, these cells suppress in an antigen-nonspe-
cific manner (for review see references 1–3).
T cells constitutively expressing CD25 are stably anergic
and suppressive, and control various autoimmune diseases
such as gastritis, thyroiditis, and autoimmune diabetes in
NOD mice (4). They arise spontaneously during ontogeny
and are present in the periphery of normal naive mice.
Therefore, CD4
 
  
 
CD25
 
  
 
T cells are “naturally occurring”
regulatory cells, whereas Tr1 are induced mainly in the
presence of IL-10 and TGF-
 
 
 
. Levings et al. (5) have
clearly demonstrated at the clonal level that Tr1 and CD4
 
 
 
CD25
 
  
 
T cells represent two distinct subsets of regulatory
cells with different cytokine production profiles.
It is still unclear whether a distinct subtype or activation
status of DC exists that promotes the differentiation of reg-
ulatory rather than effector T cells from naive precursors.
In vitro and in vivo observations suggest that immature
DCs may induce the differentiation of Treg in mice and
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Abbreviations used in this paper:
 
 CFSE, 5,6-carboxyfluorescein diacetate
succinimidyl ester; TLR, Toll-like receptor; Treg, regulatory T cells.T
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humans. However, these Treg seem to involve IL-10–
induced Tr1 cells rather than the naturally occurring CD4
 
 
 
CD25
 
  
 
population.
It is intriguing that differentiation of effector cells and
homeostasis of CD25-expressing Treg are similarly depen-
dent on TCR triggering, costimulatory signaling, CD40
engagement, and/or IL-2 production. Stimulation via
TCR is required for Treg to exert suppression. Of note,
very low doses of antigen are required, suggesting that Treg
display higher antigen sensitivity than effector T cells (6).
IL-2 seems to have a crucial role in the development and
maintenance of the CD4
 
  
 
CD25
 
  
 
population in vitro and
in vivo (7) and in the induction of their protective function
in a mouse model of spontaneous experimental autoim-
mune encephalomyelitis (8). Kumanogoh et al. (9) have
shown that the CD4
 
  
 
CD25
 
  
 
subpopulation is markedly
reduced in CD40-deficient mice and that CD40–CD40L
defective interactions can lead to autoimmunity. The es-
sential role of B7/CD28 costimulation in the homeostasis
of Treg has been illustrated in NOD mice. Indeed, sponta-
neous diabetes appears exacerbated in both B7-1/B7-2–
and CD28-deficient NOD mice and correlates with a pro-
found decrease in the number of CD4
 
  
 
CD25
 
  
 
T cells (4).
Consistent with this finding, agonistic anti-CD28 mAbs
have been shown to drive expansion of Treg in vitro and in
vivo (10).
These observations prompted us to investigate whether
Treg control immune responses induced by mature DCs
that express high levels of antigen–MHC complexes and
costimulatory molecules, secrete IL-2 themselves, and in-
duce IL-2 production by T lymphocytes.
 
Materials and Methods
 
Mice
 
BALB/c and C57BL/6 mice were purchased from Harlan
Nederland. OT-II mice, transgenic for 
 
  
 
-TCR reactive with
the I-A
 
b
 
–restricted 323–339 peptide of OVA, and OT-I mice,
transgenic for 
 
  
 
-TCR reactive with the H-2K
 
b
 
–restricted 257–
264 peptide of OVA, were provided by P. Dubois (GlaxoSmith-
Kline, Rixensart, Belgium) with the permission of W.R. Heath
(The Walter and Eliza Hall Institute, Victoria, Australia). All mice
were housed in our pathogen-free facility and used at 6–9 wk of
age. The experiments were performed in compliance with the
relevant laws and institutional guidelines.
 
Reagents and Antibodies
 
The OT-II OVA peptide (chicken OVA peptide 323–339
ISQAVHAAHAEINEAGR) and the OT-I OVA peptide
(chicken OVA peptide 257–264 SIINFEKL) were purchased
from Neosystem. KLH was purchased from Calbiochem. LPS
from 
 
Escherichia coli
 
 (serotype 055:B5) was purchased from Difco
Laboratories and 1826 CpG ODN (5
 
 
 
-TCC ATG ACG TTC
CTG ACG TT-3
 
 
 
) was purchased from Eurogentec Bel S.A. The
mAbs used were PC61 (rat IgG1 anti–mouse CD25; produced in
house; reference 11), 7D4 (rat IgM anti–CD25; BD Biosciences),
N418 (hamster anti–CD11c; produced in house), and GL-1 (rat
IgG2a anti–CD86; produced in house). Propidium iodide was
purchased from Sigma-Aldrich. 5,6-carboxyfluorescein diacetate
succinimidyl ester (CFSE) was purchased from Molecular Probes.
 
Purification of Splenic DCs
 
Mice were injected i.p. with 10 
 
 
 
g recombinant human Fms-
like tyrosine kinase 3 ligand (human Chinese hamster ovary cell–
derived; produced at Amgen) for 9 consecutive days. Spleen cells
were digested with collagenase type 3 (Worthington Biochemi-
cals), further dissociated in Ca
 
2
 
 
 
-free medium, and separated into
low and high density fraction on a Nycodenz gradient (Nycomed).
 
Mature (Cultured) DCs.
 
Low density cells were cultured for 2 h
in RPMI 1640 containing 2% Ultroser HY (Life Technolo-
gies), nonadherent cells were eliminated by vigorous pipetting,
and adherent cells were further cultured overnight at 37
 
 
 
C. After
overnight culture, nonadherent cells contained at least 90% of
DCs, as assessed by morphology and specific staining (unpub-
lished data). For the experiment depicted in Fig. 2 C (comparison
of immature and mature DCs), immature DCs, purified as de-
scribed below, were induced to mature during overnight culture
in presence of 20 ng/ml mouse GM-CSF.
 
Immature (Freshly Isolated) DCs.
 
The low density fraction was
separated according to CD11c expression by incubation with
anti-CD11c–coupled microbeads followed by one passage over a
MACS column (Miltenyi Biotec).
 
Antigen Pulsing
 
DCs were incubated with 30 
 
 
 
g/ml KLH during overnight
culture of low density spleen cells; with OVA peptide at the end
of purification steps for 1 h and 30 min at 4
 
 
 
C (5 
 
 
 
g/ml OT-I
peptide and 50 
 
 
 
g/ml OT-II peptide).
 
FACS
 
® 
 
Analysis
 
Purified DCs were double stained for CD11c expression using
PE-conjugated N418 and for CD86 expression using FITC-con-
jugated GL1. Peripheral blood mononuclear cells, splenocytes,
and LNs were double stained for CD4 expression using PE-con-
jugated L3T4 (BD Biosciences) and for CD25 expression using
FITC-conjugated 7D4 (BD Biosciences). The cells were gated
based on characteristic forward and light scatter, and analyzed on
a FACSort™ (Becton Dickinson).
 
Immunization Protocol
 
Antigen-pulsed DCs were administered at a dose of 3 
 
  
 
10
 
5
 
cells into the hind and/or fore footpads according to a protocol
described by Inaba et al. (12). When indicated, some groups of
animals received one i.p. injection of 1 mg anti-CD25 mAb
(PC61) 3–35 d before immunization. Draining popliteal and axil-
lary LNs were harvested 5 d after immunization.
When indicated, recipient mice were transferred 3 d before
immunization with CFSE-labeled OT-II (equivalent of 10
 
6 
 
trans-
genic T cells) or OT-I (equivalent of 5 
 
  
 
10
 
5 
 
transgenic T cells)
cells. CFSE labeling: splenic and LN cells from transgenic mice
(10
 
7 
 
cells/ml) were incubated with CFSE (0.5 
 
 
 
M in RPMI) for
10 min at 37
 
 
 
C. Cells were washed in RPMI containing 10%
FCS and then in PBS, and injected i.p.
 
Antigen-specific T Cell Response after In Vivo Priming
 
LN cells were cultured in Click’s medium supplemented with
0.5% heat-inactivated mouse serum and additives, with or with-
out antigen (KLH or OVA peptide). The proliferation was mea-
sured as thymidine incorporation during the last 16 h of a 3-d
culture. Culture supernatants were assayed for IFN-
 
 
 
, IL-4, andT
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IL-5 after 72 h of incubation. No IL-4 nor IL-5 was detected in
recipients which were transferred with transgenic T cells.
 
In Vivo CTL Assay (13)
 
Splenocytes and LN cells from C57BL/6 mice were pulsed or
not with 5 
 
 
 
g/ml OT-I peptide and labeled with CFSE. Peptide-
pulsed cells were labeled with CFSE at a final concentration of 5
 
 
 
M and unpulsed cells were labeled at a 10-fold lower concen-
tration by incubation for 10 min at 37
 
 
 
C. The two cell popula-
tions were mixed at 1:1 ratio and 4–5 
 
  
 
10
 
7 
 
cells were injected
i.v. into recipient mice. The percentage of antigen-specific lysis
in vivo is calculated as follows: (1 
 
  
 
number of CFSE
 
hi 
 
cells/
number of CFSE
 
lo 
 
cells) 
 
  
 
100.
 
Results
 
In Vivo Depletion of CD4
 
  
 
CD25
 
  
 
Population.
 
Natu-
rally occurring Treg have been shown to constitutively ex-
press IL-2R
 
  
 
(CD25) chain and represent 5–10% of periph-
eral blood CD4
 
  
 
cells in mice. As previous studies have
shown that anti-CD25 mAb was capable of depleting
CD25
 
  
 
cells in vivo (14, 15), 1 mg PC61 was injected i.p.
into C57BL/6 mice. Depletion of the IL-2R
 
 
 
  
 
cells was
assessed by flow cytometry using a mAb specific for a dis-
tinct epitope (7D4), which confirmed that very few of them
remained (from 10% to 1–2%; Fig. 1). Kinetic studies re-
vealed that injection of anti-CD25 mAbs led to a selective
loss of CD4
 
  
 
CD25
 
  
 
T cells in blood for at least 30 d and
that a replenishment of the population was observed 50 d
after treatment (Fig. 1 A). Further analysis of CD4
 
  
 
CD25
 
 
 
population in lymphoid organs showed that these cells were
markedly depleted from spleen and LNs on days 3 and 15
after injection of 1 (Fig. 1, B) or 0.25 mg (unpublished data)
anti-CD25 mAb. FACS
 
® 
 
analysis of splenic populations in-
dicated that CD4, CD8, B, NK, granulocytes, DC, and
macrophage populations were unaltered in CD25-treated
animals (unpublished data). Furthermore, CD4 T cells from
CD25-depleted mice displayed higher reactivity when
stimulated in vitro with allogeneic mature DCs as compared
with CD4 T cells from untreated animals (unpublished
data). The response is similar to the one of sorted CD4
 
 
 
CD25
 
  
 
cells and is down-regulated by the addition of puri-
fied CD25
 
  
 
cells, suggesting that Treg were selectively de-
pleted in PC61-treated animals (unpublished data).
 
In Vivo Depletion of CD25
 
  
 
Cells Enhances the Develop-
ment of IFN-
 
 
 
–producing CD4
 
  
 
T Cells by Mature DCs In
Vivo.
 
To test whether Treg control the induction of T
cell development by mature DCs in vivo, we transferred
splenic DCs that have undergone spontaneous maturation
in culture. In a first set of experiments, splenic DCs, pulsed
with protein antigen (KLH) during the purification steps,
were injected into the footpads of syngeneic animals that
were depleted or not of CD25
 
  
 
cells 7 d earlier. The im-
mune response was analyzed 5 d later in the draining LNs.
The data in Fig. 2 A indicate that administration of KLH-
pulsed mature DCs in treated and untreated recipients re-
sulted in similar T cell priming as assessed by KLH-depen-
dent proliferation in culture (left). Analysis of the cytokines
released by LN cells upon antigenic challenge in vitro re-
vealed that mature DCs sensitized cells producing IFN-
 
 
 
,
IL-4, and IL-5 in untreated recipients, as shown previously
(16). Of note, injection of DCs in CD25-depleted mice in-
duced the activation of cells secreting higher levels of IFN-
 
 
 
and lower levels of IL-4 and IL-5 (Fig. 2 A and data not de-
picted for IL-5). Similarly, a polarized Th1 response was ob-
served in recipients that were treated 35 d earlier with anti-
CD25 mAbs (Fig. 2 B), ruling out any possible interference
of residual anti-CD25 mAb on T cell activation or DC
function. It is noteworthy that T cells from CD25-treated
mice displayed an increased IFN-
 
  
 
production in response
to low antigen doses (see the shift in the dose response curve
in Fig. 2, A and C) while retaining similar proliferative ca-
pacities. The increase in antigen sensitivity ranged between
10- and 100-fold in over 12 independent experiments.
Next, we tested the immune response induced by imma-
ture versus mature DCs. To enhance the frequency of pep-
tide-specific CD4
 
  
 
T lymphocytes, unirradiated mice were
transferred with OT-II transgenic T cells, the majority of
which express a TCR specific for the OVA peptide 323–
339 in the context of I-A
 
b
 
. Transferred recipients were
treated or not with anti-CD25 mAbs and injected with im-
mature or mature DCs pulsed with OVA peptide. Imma-
ture DCs were freshly isolated from spleen and expressed
lower levels of CD86 as compared with mature DCs (Fig.
2 C, insert). Injection of immature splenic DCs failed to in-
duce Th1 priming in vivo. Therefore, we tested whether
depletion of Treg would restore Th1 priming by immature
DCs. The data in Fig. 2 C clearly demonstrate that injec-
Figure 1. Injection of anti-CD25 mAb results in selective loss of
CD25  cells. Mice were injected with 1 mg anti-CD25 mAb (PC61) and
analyzed by flow cytometry at the indicated days after treatment. Data are
expressed as percentage of CD4  CD25  cells amongst CD4  cells in
blood (A) or in LN, spleen, or blood (B). Two (A) and three (B) experi-
ments were performed with similar results. Data are shown for individual
mouse (A) or as mean   SD of three mice tested individually (B).T
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tion of freshly isolated DCs in untreated or depleted mice
did not sensitize Th1 cells. Collectively, these observations
show that Treg selectively down-regulate Th1 responses
induced by mature DCs.
DC-derived IL-10 Is Not Required for Treg Function. IL-
10 has been shown to be a critical factor for the differentia-
tion of IL-10–producing Treg of Tr1 type. Therefore, we
tested whether IL-10 production by donor DCs was re-
quired for the regulatory function of CD4  CD25  T cells.
There is evidence that among splenic DCs, the CD8  ,
but not CD8  , population produces IL-10 (17, 18). We
immunized mice by injection of KLH-pulsed CD8   DCs,
a protocol that has been shown to direct the development
of Th2-type cells (16). Of note, the polarized Th2-type re-
sponse (high IL-4) induced by WT CD8   DCs was
skewed toward a polarized Th1-type response (high IFN- )
in the absence of Treg (Fig. 3 A, DC wt). CD8   DCs
from IL-10 KO mice induced a mixed Th1/Th2 response
in untreated recipients and a polarized Th1 response in
PC61-treated mice (Fig. 3 A, DC IL-10 KO). These ob-
servations indicate that induction and/or function of Treg
in the LNs is not directed by DCs that secrete IL-10.
The Increased Th1 Responses in Treg-depleted Recipients Do
Not Require IL-12 nor IFN-  Production by DCs. Next,
we tested whether IL-12 and IFN-  production by DCs
were required for enhanced Th1 priming in deleted recipi-
ents. We immunized mice with KLH-pulsed CD8   DCs
(to enhance the amplitude of the Th2 to Th1 shift) isolated
from mice deficient for IL-12 or IFN- , a protocol that in-
duces Th2 priming (Fig. 3 B). Treatment with PC61 mAb
resulted in the development of a polarized Th1 response in
mice injected with IL-12– or IFN- –deficient DCs, show-
ing that production of these cytokines by DCs themselves is
not required for Th1 priming in these conditions (Fig. 3 B).
Role of Toll-like Receptor (TLR) Engagement. Interest-
ingly, recent studies have suggested that ligation of TLRs
on DCs may overcome CD4  CD25  T cell–mediated
suppression. Pasare and Medzhitov (19) have reported that
LPS-treated DCs produce a cytokine (IL-6) that acts on re-
sponder T cells and renders them refractory to Treg-medi-
ated suppression in vitro and in vivo. Similarly, George et
al. (20) have shown that Treg suppression of T helper pro-
liferation is broken with potent stimulation, i.e., high anti-
gen dose and activated DCs. These observations prompted
us to test whether ligation of TLR on DCs may induce an
immune response that would not be under the control of
Treg. The data in Fig. 4 show that injection of untreated or
LPS-treated (unseparated splenic) DCs, pulsed with KLH,
induced the development of a mixed immune response and
that CpG-treated DCs induced a polarized Th1 response.
Depletion of Treg further enhanced the differentiation of
IFN- –producing cells and down-regulated the production
of IL-4 by LN cells from mice primed with untreated or
LPS-treated DCs.
Depletion of Treg Enhances the Development of IFN- –pro-
ducing CD8 T Cells and CTLs by Mature DCs In Vivo.
Next, we tested whether CD8 T cell priming by mature
DCs is similarly under the control of Treg. To study the
Figure 2. Depletion of Treg results in
enhanced development of IFN- –produc-
ing CD4  T cells by mature DCs in vivo.
KLH-pulsed mature DCs were injected into
the footpads of syngeneic mice that were ei-
ther untreated (open symbols/bars) or in-
jected with 1 mg PC61 (solid symbols/bars)
7 (A) or 35 d (B) earlier. Draining LNs were
harvested 5 d later and cultured with graded
doses (A) or 2  g/ml (B) KLH. Prolifera-
tion and lymphokine production were mea-
sured as indicated in Materials and Methods.
(C) C57BL/6 mice were transferred with T
cells from TCR transgenic OT-II mice and
immunized s.c. with OVA peptide–pulsed
immature or mature DCs (3    105 DC/
footpad). Proliferation and IFN-  produc-
tion were measured in the supernatant of
LN cells harvested 5 d after immunization
and cultured with graded doses of OVA
peptide. The insert in C shows the CD86
expression by immature versus mature DCs.
Five (A) and three (B and C) experiments
were performed with similar results. Data
are shown as mean   SD of three individual
mice in each group.T
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activation of MHC class I–restricted CD8  T lymphocytes,
unirradiated mice were transferred with OT-I transgenic T
cells, the majority of which express a TCR specific for the
OVA peptide 257–264 in the context of H-2Kb. Trans-
ferred recipients were treated or not with anti-CD25 mAbs
and injected with mature DCs pulsed with OVA peptide.
The data in Fig. 5 show that antigen-specific IFN-  pro-
duction was strongly enhanced upon PC61 treatment (Fig.
5 A) and that LN cells from CD25-treated mice were hy-
perreactive as indicated by enhanced responsiveness to low
antigen stimulation. To monitor the differentiation of
OVA-specific CTLs in vivo, untransferred mice were im-
munized by injection of mature DCs, pulsed with OT-I
peptide, into the hind footpads. 5 d later, CTLs were as-
sayed in vivo by a method originally described by Aichele
et al. (13). In brief, splenocytes, pulsed or not with OT-I
peptide, were labeled with distinct intensities of CFSE
fluorescence, mixed 1:1, and transferred i.v. as indicator
cells into naive or primed recipients. Fluorescence-acti-
vated cell sorter analysis of LN and spleen revealed two
CFSE-labeled indicator cells of comparable size in naive
mice (Fig. 5 B) or in mice injected with unpulsed DCs (not
depicted). Percentage of peptide-specific lysis was calcu-
lated by comparing the relative loss of peptide-pulsed ver-
sus unpulsed indicator cells and revealed a lysis of 0–10% in
the absence of immunization. By contrast, the OVA pep-
tide–loaded CFSEhi cell population was strongly reduced in
numbers when compared with the unloaded CFSElo popu-
lation in the draining LNs of mice primed with mature
DCs, treated or not with PC61. Of note, the reduction of
OVA peptide–pulsed indicator cells was more pronounced
in nondraining LNs and spleens of CD25-treated recipients
as compared with untreated mice (Fig. 5 B).
Discussion
The data presented herein underscore the crucial role of
DCs in the regulation of immunity and show that the func-
tion of mature DCs is under the control of the naturally
occurring CD4  CD25  cells in vivo. Our observations
Figure 3. (A) DC-derived IL-10 is not required for Treg function.
CD8   DCs from WT or IL-10–deficient mice were pulsed with KLH
and injected into the footpads of untreated or depleted WT recipients. 5 d
later, LN cells were harvested and cultured with 2  g/ml KLH. The
IFN-  and IL-4 content was measured in the supernatant at 72 h. (B) The
enhanced Th1 priming is independent of DC-derived IL-12 and IFN- .
Purified CD8   DC from IL-12 or IFN-  KO mice were pulsed over-
night with KLH and injected into the footpads of WT recipients treated
or not with anti-CD25 mAb. IFN-  and IL-4 were measured in the su-
pernatant of LN cells harvested 5 d after immunization and cultured with
2  g/ml KLH. Four (A and B) and three (C) experiments were performed
with similar results. Data are shown as mean   SD of three individual
mice in each group.
Figure 4. Engagement of TLRs on DCs did not prevent the suppres-
sive effect of Treg. Mature DCs, which have been pulsed with KLH dur-
ing overnight culture, were further incubated with medium alone, 500
ng/ml CpG, or 100 ng/ml LPS for 3 h at 37 C. DCs were washed and
injected into the footpads of untreated or CD25-depleted recipients.
IFN-  and IL-4 were measured in the supernatant of LN cells harvested
5 d after immunization and cultured with 2  g/ml KLH. Each symbol
represents production of cytokine of individual animals and vertical bars
are the mean results of five to six mice. Data shown are pooled from two
experiments and are representative of three independent experiments.T
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suggest that Treg exert a negative feedback mechanism on
immune responses specific for nonself antigens and influ-
ence the character of T cell differentiation by selectively
dampening Th1-type responses and CTLs. As the effector
mechanisms that protect the host from invading microor-
ganisms can induce immune-mediated pathologies if not
properly regulated, Treg may constitute a physiological ho-
meostatic checkpoint.
Recent evidence suggests that DCs are involved in im-
munity and tolerance, depending on their maturation state.
DCs in the steady state seem to transport antigen from the
trachea and the intestine to the draining LNs, inducing a
state of tolerance (21, 22). Targeting an antigen on nonac-
tivated DCs resulted in abortive immune responses leading
to a state of antigen-specific unresponsiveness in a murine
model (23). Activation of DCs restored the immunostimu-
latory properties of DCs in the same conditions. In hu-
mans, injection of immature DCs pulsed with influenza
peptide into volunteers rendered them unable to respond
to a subsequent immunogenic stimulus (24). Based on
these observations, it was suggested that immature DCs
constitutively expressing self-antigens would directly or in-
directly induce a state of peripheral tolerance. Indirect
mechanisms of tolerance may include the differentiation/
activation of Treg.
However, although the type of Treg has not been iden-
tified in all studies, there is evidence that immature DCs
produce IL-10 and induce a state of tolerance by triggering
the differentiation and function of Tr1 cells in mice and
humans (25, 26). By contrast, our observations suggest that
mature DCs induce a regulatory mechanism mediated by
CD4  CD25  T cells. Depletion of Treg did not restore
Th1 priming by immature DCs in our experimental set-
ting, suggesting that the lack of differentiation is not due to
CD4  CD25  cells. Although we cannot rule out the pos-
sibility that Treg are induced by immature DCs at a time
when anti-CD25 mAbs are no longer present, we found
that the number of CD4  CD25  T cells was not enhanced
in the blood of mice that received three to five injections
of immature DCs (unpublished data). Experiments are un-
derway to test whether Tr1 cells are induced in recipients
primed with one injection of immature DCs.
It is noteworthy that both DCs and Treg express several
TLRs, suggesting that their function can be regulated by
microbial products. An interesting study has suggested that
DCs, activated by TLR ligand, would induce an immune
response that is refractory to inhibition by Treg (19). We
found, however, that splenic DCs that have matured spon-
taneously in culture or have been treated with LPS or CpG
activate immune responses that remain sensitive to Treg
function. Caramalho et al. (27) have further shown that
Treg are activated by LPS. Collectively, these observations
suggest that the feedback mechanism mediated by Treg is
enhanced by microbial agents.
Our results show that Treg control immunity to foreign
antigens (KLH protein and OVA class I and II peptides).
These observations are consistent with reports demonstrat-
ing pathogen-specific Treg in viral, bacterial, fungal, and
parasitic infection. In particular, during infection by Leish-
mania major, CD4  CD25  T cells accumulate in the der-
mis where they prevent elimination of the parasite by ef-
fector cells. Interestingly, the persistence of parasite appears
essential for immunity to reinfection (28). Whether deple-
tion of Treg may affect the onset of memory responses will
be an important issue to address in future experiments.
The molecular mechanisms responsible for regulatory
activity are still a matter of speculation. Thornton and She-
vach (29) have demonstrated that Treg suppress the prolif-
eration of conventional T cells by specifically inhibiting the
production of IL-2. The role of cytokines (IL-10, TGF- )
and cell-associated molecules (CTLA-4, GITR) remains
controversial in vivo (for review see reference 2). IL-10–
dependent and –independent mechanisms have been found
to promote parasite persistence in mice infected with L.
Figure 5. Enhanced development of IFN- –producing CD8 T cells
and CTLs by mature DCs in CD25-depleted recipients. (A) Mature
splenic DCs, pulsed with OT-I OVA peptide, were injected into the
footpads of syngeneic animals, which were transferred 2 d earlier with
cells from OT-I transgenic mice. A group of mice was treated 7 d earlier
with PC61. LN cells were harvested 3 d after DC injection and cultured
with graded doses of OVA OT-I peptide. IFN-  production was mea-
sured after 72 h of culture. Data are shown as mean of cytokine produc-
tion by three individual mice   SD. Four experiments were performed
with similar results. (B) Mature DCs, pulsed with OT-I peptide, were in-
jected into the hind footpads of untransferred recipients. The cytotoxic
activity was assayed in vivo 5 d after immunization. Data represent the
relative loss of antigen-pulsed indicator cells (CFSEhi) as compared with
unpulsed indicator cells (CFSElo). Data are shown as mean of the percent
antigen-specific lysis by three to four individual mice   SD. The groups
indicated by asterisks are significantly different from control. Student’s t
test, *, P   0.02 or **, P   0.005. Three experiments were performed
with similar results.T
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major (28). A role of IL-10 would be consistent with the se-
lective inhibitory effect of Treg on Th1 responses. Our
data further show that the enhanced Th1 responses in
CD25-depleted mice are independent from IL-12 and
IFN-  production by transferred DCs. These findings were
unexpected as we have previously shown that the activa-
tion of Th1 responses by DCs correlates with their produc-
tion of IL-12p70 heterodimer and IFN-  (17).
There is little information about the trafficking of Treg
in vivo. CD4  CD25  T cells were found in recipient lym-
phoid tissues after transplantation and at the graft site (30).
Our data show that Treg limit the development of Th1
cells in the LNs draining the site of injection. Additionally,
these cells may migrate to the inflammatory site where that
may inhibit the effector function of differentiated Th1 cells.
Our data show that both CD4 and CD8 lymphocytes are
under the control of CD4  CD25  Treg. The IFN-  pro-
duction by MHC class I–restricted CD8 T cells was
strongly enhanced upon Treg depletion. The CTL activity
was assessed by an in vivo assay and was significantly in-
creased in the spleen and nondraining LNs. Our observa-
tions are consistent with recent reports demonstrating that
the numbers of CD4  CD25  T cells inversely correlated
with the numbers of memory phenotype CD8  T cells
with age in mice (31) and that CD4  CD25  T cells regu-
late human CD8  T cell function in vitro (32).
In conclusion, CD4  CD25  Treg not only inhibit im-
mune responses against self-antigens (33, 34), but also
suppress those against microbes (28) and innocuous anti-
gens (this paper). It has been suggested that the stage of
activation of DCs may tune the degree of suppressive ac-
tivity of Treg, with resting DCs activating Treg and ma-
ture DCs suppressing Treg (35). However, our results in-
dicate that Treg dampen the immune responses induced
by fully competent DCs in vivo. We believe that DCs
that are able to discriminate innocuous self from microbial
nonself may regulate the immune responses to self and
nonself indirectly through distinct populations of suppres-
sor cells. Thus, immature DCs would induce the differen-
tiation of IL-10–producing Tr1 cells, whereas mature
DCs would promote the survival and/or function of natu-
rally occurring CD4  CD25  Treg. The combined action
of DCs in the thymus and immature DCs in the periphery
(via Tr1) would strongly limit the number of precursor T
cells specific for self-antigens. Therefore, CD4  CD25 
Treg would have a strong suppressive effect on “low”
self-specific responses, thereby avoiding autoimmunity.
The same Treg would limit “strong” Th1 responses spe-
cific to microbial antigens to avoid excessive inflamma-
tory responses and serious damage to the host. The IL-
10–induced Tr1 cells and constitutive CD4  CD25  Treg
would therefore differentially regulate effector immune
responses whether they are specific to a self-constituent
(presented by immature DCs) or to a microbe (presented
by maturing DCs).
Our observations suggest that presentation of tumor an-
tigen by mature DCs and silencing of CD4  CD25  Treg
may synergistically augment tumor-specific immunity and
open novel opportunities to optimize DC-based immuno-
therapy in cancer patients.
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